The new system consists of a small, thin patch that is pressed against a patient’s arm during medical treatment and measures drugs in their bloodstream painlessly without drawing any blood. The tiny needle-like projection, less than half a milimetre long, resembles a hollow cone and doesn’t pierce the skin like a standard hypodermic needle.
“Many groups are researching microneedle technology for painless vaccines and drug delivery,” said researcher Sahan Ranamukhaarachchi, a PhD student and Vanier scholar in UBC’s faculties of applied science and pharmaceutical sciences, who developed this technology during a research exchange at PSI. “Using them to painlessly monitor drugs is a newer idea.”
Microneedles are designed to puncture the outer layer of skin, which acts as a protective shield, but not the next layers of epidermis and the dermis, which house nerves, blood vessels and active immune cells.
The microneedle created by Ranamukhaarachchi and his colleagues was developed to monitor the antibiotic vancomycin, which is used to treat serious infections and is administered through an intravenous line. Patients taking the antibiotic undergo three to four blood draws per day and need to be closely monitored because vancomycin can cause life-threatening toxic side effects.
The researchers discovered that they could use the fluid found just below the outer layer of skin, instead of blood, to monitor levels of vancomycin in the bloodstream. The microneedle collects just a tiny bit of this fluid, less than a millionth of a millilitre, and a reaction occurs on the inside of the microneedle that researchers can detect using an optical sensor. This technique allows researchers to quickly and easily determine the concentration of vancomycin.
“This is probably one of the smallest probe volumes ever recorded for a medically relevant analysis,” said Urs Hafeli, associate professor in UBC’s faculty of pharmaceutical sciences.
“The combination of knowhow from UBC and PSI, bringing together microneedles, microfluidics, optics and biotechnology, allowed us to create such a device capable of both collecting the fluid and performing the analysis in one device,” said Victor Cadarso, a research scientist and Ambizione Fellow at PSI.
The microneedle monitoring system, described in a paper published earlier this month in Scientific Reports, was developed out of a research collaboration between Hafeli and Boris Stoeber, a professor in UBC’s faculty of applied sciences, and is being commercialized by the UBC spin-off Microdermics Inc.
The Latest on: Microneedle
via Google News
The Latest on: Microneedle
- SLA 3D Printing For Microneedle Transdermal Drug Delivery Systemson October 2, 2020 at 5:00 pm
A curated collection of industry and product deep-dives. I met Jos Burger when I was working for Shapeways years ago. He’s astute, very bright and a natural leader who later worked at Ultimaker ...
- Shoppers say this $20 derma roller helped with hair growthon October 2, 2020 at 9:56 am
For many, hair loss can be an extremely frustrating experience. Many have even recommended it for alopecia, baldness and other hair issues. A No. 1 best seller on Amazon, the Sdara Skincare ...
- Zosano Pharma Receives Preliminary FDA Communication on Qtrypta™ NDAon September 30, 2020 at 3:13 pm
The company’s transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients.
- Zosano Pharma Receives Preliminary FDA Communication on Qtrypta(TM) NDAon September 30, 2020 at 2:55 pm
in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (NDA). A DRL is used by the FDA to convey preliminary comments on deficiencies identified ...
- Zosano Pharma Receives Preliminary FDA Communication on Qtrypta™ NDAon September 30, 2020 at 2:40 pm
(GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company today announced that it has received a discipline review letter (DRL) from the U.S. Food and ...
- Zosano Pharma Receives Preliminary FDA Communication on Qtrypta™ NDAon September 30, 2020 at 10:40 am
in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (NDA). A DRL is used by the FDA to convey preliminary comments on deficiencies ...
via Bing News